AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03574974 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Feedback
Description: Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions.
Study NCT03692637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-Mesothelin Car NK Cells
Description: anti-Mesothelin Car NK Cells injection
Study NCT01939730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
Study NCT01939730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg subcutaneously 3 times a week for 8 weeks.
Study NCT02440893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Study NCT01290302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luitpold Azacitidine
Description: Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
Study NCT01290302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vidaza®
Description: Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
Study NCT01503983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
Study NCT01503983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
Study NCT01503983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
Study NCT04020419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PediaBerry
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
Study NCT04020419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PediaBerry
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
Study NCT02717728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug group Fascia iliaca nerve block
Description: Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.
Study NCT02717728 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group sham nerve block
Description: Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.
Study NCT03981016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: * blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery
Study NCT00545623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
Study NCT00545623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response
Description: listening to CDs with verbal instructions of techniques to elicit relaxation response
Study NCT00545623 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
Study NCT05419167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-COVID
Description: The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
Study NCT01381926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
Study NCT01381926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
Study NCT01381926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
Study NCT01381926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
Study NCT00245180 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Study NCT03889353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI sessions
Description: up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
Study NCT00963976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Study NCT00963976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Study NCT00707967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT00707967 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with the adjuvant system.
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT00707967 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with physiological saline
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT04380376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Inhalations with low doses of Melphalan for 7-10 consequent days
Study NCT04380376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: the patients will receive only SOC (standard of care) treatment
Study NCT02938117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling exercises
Study NCT03248648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
Study NCT03248648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
Study NCT00588146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha2b
Description: Weekly subcutaneous injection of 1 microgram/kg/week
Study NCT00588146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care
Study NCT02217111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventures in Voice: Pediatric Voice Therapy
Study NCT00678847 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KFH NOVO (inactive) + SCT
Description: inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
Study NCT00678847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KFH Novo (BEST) + SCT
Description: 2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
Study NCT01701544 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NBM DBS
Description: Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
Study NCT01701544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBM DBS
Description: Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
Study NCT00667992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide HFA
Description: standard daily inhaled dose
Study NCT00667992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide CFC
Description: standard daily inhaled dose
Study NCT02915172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1.
Study NCT02915172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
Study NCT04553614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based HIIT
Description: Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
Study NCT04553614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual exercise referral scheme procedure.
Study NCT01258478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
Study NCT01021618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
Study NCT01021618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-limited exercise
Description: Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
Study NCT00196157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: linear anatomically oriented ablations
Description: linear lesions to ablate persistent atrial fibrillation
Study NCT01258478 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT02202798 — intervention group
Intervention type: DEVICE
Intervention: Syringe device
Study NCT00366782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
Study NCT00366782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50
Study NCT00366782 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rB/HPIV3 vaccine
Study NCT01418911 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire only
Study NCT02408731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
Study NCT03958188 — intervention group
Intervention type: OTHER
Intervention: Standardized computerized tomography (CT) reading grid for preoperative planning
Description: Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital.
Study NCT03559283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking and Record Cortical Activity
Description: The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer.
Study NCT02403050 — intervention group
Intervention type: DEVICE
Intervention: Fiducial markers
Description: 2 fiducial markers (Visicoils) to be placed in the tumor area
Study NCT03925337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Aided Diagnostic Software
Description: The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
Study NCT04260997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri BNR17™ capsule
Description: Once per day (QD), 12 weeks
Study NCT04260997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Once per day (QD), 12 weeks
Study NCT04394702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Shape Single-file rotary system
Description: rotational single file system used for mechanical debridement of root canals
Study NCT04394702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual stainless steel K-file
Description: sequential manual filing with stainless steel K-files
Study NCT04235426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Description: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Study NCT04235426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30 patients went to surgical procedure
Description: 30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
Study NCT04235426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection
Description: Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
Study NCT02608385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
Study NCT02608385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg) given every 3 weeks.
Study NCT03981146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 60 Minute IV Infusion
Study NCT03335813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoesophageal Brachytherapy
Description: Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
Study NCT04153474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: large-bore nephrostomy tube (LBNT)
Description: large-bore 22 french nephrostomy tube (LBNT)
Study NCT04153474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: small-bore nephrostomy tube (SBNT)
Description: small-bore 14 french nephrostomy tube (SBNT)
Study NCT01137487 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: monitoring of residual gastric volume
Description: measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
Study NCT01137487 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: not monitoring of residual gastric volume
Description: no measurements of residual gastric volume
Study NCT01747096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga-DOTANOC
Study NCT03512353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
Study NCT03512353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
Study NCT01085708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 10 mg normal tablet
Study NCT01085708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 1 granule containing rabeprazole 10 mg
Study NCT01085708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 2 granules containing rabeprazole 10 mg
Study NCT00196157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focal electrophysiological oriented ablations
Description: focal electrophysiologically guided ablations to treat persistent atrial fibrillation
Study NCT01085708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: Type 3 granules containing rabeprazole 10 mg
Study NCT03534167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TODAY! App and Coaching
Description: The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based.
Study NCT03464032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-135
Description: Monoclonal anti-PD-L1 antibody